Pure Global
NCT06361758

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC: A Single Arm, Multicenter, Phase II Trial. (SCALE)
Shanghai Zhongshan Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
Cadonilimab+Lenvatinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Zhongshan Hospital
Location
Shanghai,Guangzhou,Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 31, 2024
End date
May 31, 2027
Enrollment
30 participants
Primary outcome

Objective Response Rate (ORR) per RECIST v1.1

Summary

This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and
 safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with
 advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of
 immunotheray and antiangiogenic therapy.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06361758
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06361758 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Zhongshan Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.